ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 974

Leucine-Rich α-2 Glycoprotein Promotes Lung Fibrosis By Modulating TGF-β Signaling in Fibroblasts

Hiromi Honda, Minoru Fujimoto, Satoshi Serada, Hyun Lee, Tomoharu Ohkawara and Tetsuji Naka, Center for Intractable Immune Disease, Kochi University, Nankoku, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Fibroblasts, pulmonary fibrosis and transforming growth factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is one of the most common extraarticular manifestation of rheumatoid arthritis. ILD is characterized by progressive fibrosis of the lung parenchyma and is associated with increased morbidity and mortality. Since TGF-β is thought to play an important role in tissue fibrosis, understanding the molecular details of TGF-β signaling will provide us a novel therapeutic target for fibrotic disorders. Recently, leucine-rich α-2 glycoprotein (LRG) was reported to function as a modulator of TGF-β signaling in angiogenesis in retinal disease and cardiac remodeling. However, the role of LRG in fibrotic diseases including lung fibrosis has not yet been investigated. In this study, we aimed to investigate the involvement of LRG in lung fibrosis using an animal model of lung fibrosis.

Methods: Bleomycin was intratracheally administered to C57BL/6 (WT) mice and LRG knockout (KO) mice, and lung fibrosis was evaluated by Masson’s trichrome staining and hydroxyproline quantification in the lung. TGF-β signaling in the lung was examined by analyzing phosphorylation of Smad proteins and expression of TGF-β downstream genes. Furthermore, in vitro analysis using L929 mouse fibroblast cell line was performed to assess the effect of LRG on TGF-β signaling in fibroblasts.

Results: The amount of LRG in BALF of WT mice was increased after bleomycin treatment. Immunohistochemistry of the lung section showed that LRG was expressed in alveolar epithelial cells, bronchial epithelial cells and infiltrated immune cells in bleomycin-treated WT mouse lung. In LRG KO mice, fibrosis in the lung was less severe as indicated by attenuated Masson’s trichrome staining and lower collagen content in the lung compared with WT mice. In addition, expression of α-SMA was decreased and phosphorylation of Smad2 was reduced in the lung of LRG KO mice compared with WT mice, suggesting that fibroblast activation was inhibited in the absence of LRG. In vitro experiments indicated that LRG enhanced TGF-β-induced phosphorylation of Smad2 and expression of PAI-1 and α-SMA in fibroblasts. On the other hand, Smad1/5/8 signaling was not enhanced by LRG. Although endoglin, an accessory TGF-β receptor, is known to be essential for LRG to modulate TGF-β signaling in endothelial cells, we found that endoglin was not involved in the process of enhancing Smad2 phosphorylation in fibroblasts.

Conclusion: LRG promotes lung fibrosis by enhancing TGF-β-induced phosphorylation of Smad2 in fibroblasts and by accelerating fibroblast differentiation into myofibroblasts.


Disclosure: H. Honda, None; M. Fujimoto, None; S. Serada, None; H. Lee, None; T. Ohkawara, None; T. Naka, Practical Project for Rare/Intractable Diseases from Japan Agency for Medical Research and development (15ek0109045h0003), 2,Research collaboration with SEKISUI MEDICAL, 2.

To cite this abstract in AMA style:

Honda H, Fujimoto M, Serada S, Lee H, Ohkawara T, Naka T. Leucine-Rich α-2 Glycoprotein Promotes Lung Fibrosis By Modulating TGF-β Signaling in Fibroblasts [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/leucine-rich-%ce%b1-2-glycoprotein-promotes-lung-fibrosis-by-modulating-tgf-%ce%b2-signaling-in-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leucine-rich-%ce%b1-2-glycoprotein-promotes-lung-fibrosis-by-modulating-tgf-%ce%b2-signaling-in-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology